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Abstract
Background and Aims: Chronic infection with the hepatitis B virus (HBV) is a major health issue worldwide. Recently, single
nucleotide polymorphisms (SNPs) within the human leukocyte antigen (HLA)-DP locus were identified to be associated with
HBV infection in Asian populations. Most significant associations were observed for the A alleles of HLA-DPA1 rs3077 and
HLA-DPB1 rs9277535, which conferred a decreased risk for HBV infection. We assessed the implications of these variants for
HBV infection in Caucasians.
Methods: Two HLA-DP gene variants (rs3077 and rs9277535) were analyzed for associations with persistent HBV infection
and with different clinical outcomes, i.e., inactive HBsAg carrier status versus progressive chronic HBV (CHB) infection in
Caucasian patients (n=201) and HBsAg negative controls (n=235).
Results: The HLA-DPA1 rs3077 C allele was significantly associated with HBV infection (odds ratio, OR=5.1, 95% confidence
interval, CI: 1.9–13.7; p=0.00093). However, no significant association was seen for rs3077 with progressive CHB infection
versus inactive HBsAg carrier status (OR=2.7, 95% CI: 0.6–11.1; p=0.31). In contrast, HLA-DPB1 rs9277535 was not
associated with HBV infection in Caucasians (OR=0.8, 95% CI: 0.4–1.9; p=1).
Conclusions: A highly significant association of HLA-DPA1 rs3077 with HBV infection was observed in Caucasians. However,
as a differentiation between different clinical courses of HBV infection was not possible, knowledge of the HLA-DPA1
genotype cannot be translated into personalized anti-HBV therapy approaches.
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Introduction
Hepatitis B virus (HBV) infection remains a major public health
concern despite the existence of a potent vaccine for more than 25
years. Worldwide, two billion people have been infected and up to
350 million people suffer from chronic HBV. They are at risk of
developing liver fibrosis, cirrhosis and hepatocellular carcinoma
[1]. In Germany, the prevalence of hepatitis B surface antigen
(HBsAg), an indicator of current HBV infection, has been
estimated to be 0.6%. Up to 40% of HBsAg carriers are reported
to have a migration background from areas with higher HBV
prevalence [2,3].
Exposure to HBV results in a wide spectrum of clinical
outcomes. Progression from acute to persistent HBV infection
occurs in approximately 90% of individuals with perinatal
infection but in only 5% or less of adults [4]. Patients with
persistent HBV infection may develop chronic hepatitis B (CHB)
characterized by elevated alanine aminotransferase (ALT) en-
zymes, high HBV DNA levels and histological lesions. In contrast,
‘‘inactive’’ HBsAg carriers, who generally do not need antiviral
therapy, are characterized by persistently normal ALT values, low
HBV DNA levels (,2000 IU/mL) and no liver injury [5,6].
However, distinguishing between active and inactive HBV carriers
can be difficult due to fluctuating ALT and HBV DNA
concentrations.
Although the mechanisms of HBV persistence and factors
influencing the clinical spectrum of the disease are still not fully
understood, a complex interplay of viral, environmental and host
factors is believed to determine the different clinical outcomes of
HBV infection [4]. Moreover, family and twin studies have
pointed at the important contribution of host genetic factors
influencing the response to HBV infection [7,8]. Recently, a
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Japanese HBV carriers and controls showed a significant
association of persistent HBV infection with 11 single nucleotide
polymorphisms (SNPs) within the HLA-DP (an HLA class II
molecule) gene locus, including HLA-DPA1 and HLA-DPB1 [9].
The significant association of the two most or second-most strongly
associated SNPs at each HLA-DP locus (rs3077 on HLA-DPA1 and
rs9277535 on HLA-DPB1) were reproduced in several large
Japanese, Thai and Chinese cohorts [9,10,11,12,13]. Notably, the
A alleles of both HLA-DPA1 rs3077 and HLA-DPB1 rs9277535
were significantly associated with a decreased risk for HBV
infection. However, knowledge about variants within the HLA-DP
locus in Caucasian patients with persistent HBV infection and
their implications for clinical practice, including distinguishing
inactive HBsAg carriers from CHB patients, is sparse. Therefore,
this was assessed in the present investigation in 201 Caucasian
patients with persistent HBV infection and 235 healthy controls
who were negative for HBV serological markers.
Methods
Subjects and study design
The study followed the Declaration of Helsinki on Biomedical
Research Involving Human Subjects. Approval from the Ethics
Committee of the Medical Faculty of the J. W. Goethe University,
Frankfurt, Germany, and written informed consent from each
participating subject had been obtained. Consecutive patients with
persistent HBV infection, defined as presence of HBsAg and HBV
DNA for more than six months, were identified at the Hepatology
Outpatient Clinics of the J. W. Goethe University Hospital in
Frankfurt, Germany and the Saarland University Hospital in
Homburg, Germany. The primary aim of this study was to assess
the associations of two HLA-DP polymorphisms with disease
severity in patients with persistent HBV infection. Therefore,
detailed clinical data, including repeated ALT and HBV DNA
measurements, were collected when available to differentiate
between different courses of persistent HBV infection. This
included low-viremic ‘‘inactive’’ HBsAg carrier status and active
chronic HBV (CHB) infection according to current guideline
definitions [5,6]. In addition, HBV genotypes were also collected.
Unrelated Caucasian subjects (n=235), tested negative for
HBsAg, anti-HBc, anti-HCV and anti-HIV antibodies at study
inclusion, served as controls. All patients and controls were of
Caucasian ethnicity by self-assignment.
Genotyping assays
Genomic DNA was extracted from 200 ml whole blood using
the EZ1 DNA Blood Kit on a BioRobot EZ1 workstation (Qiagen,
Hilden, Germany). PCR primers for amplification of HLA-DP
gene segments and the respective sequencing primers were
designed with the PyroMark Assay Design software (version
2.0.1.15; Qiagen). The following primers were used: HLA-DPA1
rs3077: forward primer: 59-GTGTTGCTGCAGGTGA-
CAAAAT-39 and reverse primer: 59-biotin-ACTGCTTTGAGG-
TAATGGATAAGG-39, HLA-DPB1 rs9277535: forward primer:
59-CCCCAAATCAAGTTTAGTGCC-39 and reverse primer: 59-
biotin-CATTCAAAAGTCCAAGCCGTAT-39. Specificity of the
primers was verified by gene alignment (http://www.ncbi.nlm.nih.
gov/Blast/). PCR reactions (25 ml assay volume) were done on a
MastercyclerH ep gradient s instrument (Eppendorf, Hamburg,
Germany) using 2.5 ml genomic DNA mixed with 0.125 ml1 0 6
HotStarTaq Plus DNA polymerase, 2.5 ml1 0 6HotStarTaq Plus
PCR Buffer, 5 ml5 6 Q-Solution, 0.5 ml dNTP mix (10 mmol/l
each), 0.05 ml of one biotinylated and one nonbiotinylated PCR
primer (100 mmol/l each) and 14.275 ml water. PCR reactions
were carried out with an initial denaturation step at 95uC for
5 min, followed by 45 cycles at 95uC for 30 s, an annealing step at
51uC (rs3077) or 56uC (rs9277535) for 30 s and an elongation step
at 72uC for 30 s and, finally, an elongation step at 72uC for 5 min.
PCR products were evaluated by capillary electrophoresis on a
QIAxel system (Qiagen).
Twenty-five ml of PCR templates were subsequently pipetted
into wells containing 3 ml of streptavidin-coated sepharose beads
(GE Healthcare Bio-Sciences, Uppsala, Sweden), 37 ml of Binding
Buffer (10 mmol/l tris[hydroxylmethyl]-aminomethan, 2 mmol/l
NaCl, 1 mmol/l EDTA, and 0.1% polyoxyethylenesorbitan
monolaureate [Tween 20] at pH 7.6) and 15 ml HPLC-purified
water. Incubation at room temperature for 10 min allowed the
biotinylated DNA strands to form specific complexes with
streptavidin-coated sepharose beads. The complexes were then
purified and separated from the non-biotinylated DNA strands by
suction on a PyroMark Q96 Vacuum Prep Workstation (Qiagen)
before they were transferred to a PSQ 96 Plate Low (Qiagen)
prefilled with 0.16 ml of 100 mmol/l sequencing primers (rs3077:
59-TCACCTCATGTGAAAACTAC-39 and rs9277535: 59-
TGCCTGATAGGACCC-39) and 39.84 ml annealing buffer
(20 mmol/l tris[hydroxymethyl]-aminomethan and 2 mmol/l
magnesium acetate tetrahydrate at pH 7.6). After heating the
plate to 80uC for 2 min in a PSQ 96 Sample Prep Thermoplate
Low (Qiagen) it was cooled to room temperature and subsequently
transferred to a PSQH 96MA System (Qiagen) for sequencing
analyses. Sequencing was performed using Pyrosequencing-
specific enzyme mix, substrate mix and nucleotides (PyroMark
Gold Q96 reagent set for SNP genotyping and mutation analysis;
Qiagen). Two samples of each genotype and SNP were
conventionally sequenced by an external laboratory (LGC
Genomics, Berlin, Germany) as positive controls. Please note that
in the present study the rs3077 T/C alleles correspond to the A/G
alleles on the reverse strand reported previously [9,11], and
contrary to the reported studies from Asian populations, the T
allele was the major allele according to the frequency in
Caucasians.
Statistics
The correspondence between the observed numbers of
homozygous and heterozygous subjects with those expected from
the Hardy-Weinberg equilibrium was checked by means of x
2
goodness-of-fit tests. A possible haploblock was identified using the
three methods implemented in the Haploview software (version
4.2 [14]), i.e., 95% confidence bounds on D9 [15], four gamete
rule [16] and Solid Spine of linkage disequilibrium (LD). LD was
analyzed by calculating parameters D9 and r
2 [17,18]. Allelic
frequencies of the SNPs were compared between (i) HBV infected
patients and healthy controls and (ii) CHB patients and inactive
HBsAg carriers using x
2 statistics (with correction of the alpha
level of 0.05 for multiple testing according to Bonferroni; SVS
7.5.4 for Linux, Golden Helix, Bozeman, MT, USA). The
dominant and recessive hereditary models were applied, i.e.,
comparing the number of wild-type subjects with the number of
carriers of minor alleles or comparing the number of homozygous
carriers of minor alleles with the rest of the subjects between the
selected subcohorts, respectively. The role of the viral genotype for
HBV disease activity was assessed by submitting the CHB or
inactive HBsAg carrier status to binary logistic regression analysis
(SPSS 20 for Linux, IBM SPSS Inc., Chicago, USA), with stepwise
inclusion of candidate factors rs3077, rs9277535, and HBV
genotype.
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Genotypes with respect to HLA-DPA1 rs3077 and HLA-DPB1
rs9277535 were available from 201 patients (128 men, mean age
42614 years) with persistent HBV infection and from 235 healthy
controls with negative HBV serological markers. The minor alleles
of rs3077 (C allele) and rs9277535 (G allele) were observed at
frequencies of 24.1% and 25.9% in HBV patients, respectively,
and in 17.8% and 24.3% of healthy controls. The two genes are
located on chromosome 6 and the SNPs are 21,839 nucleotides
apart according to the reference sequence given in the dbSNP
database (http://www.ncbi.nlm.nih.gov/SNP/, accessed on Jan-
uary 14, 2012). For this distance, the SNPs are most likely not
united on a haploblock and their linkage disequilibrium was weak
with values of D9=0.44 and r
2=0.18 in HBV patients and
D9=0.43 and r
2=0.13 in healthy controls.
Carriage of the minor HLA-DPA1 rs3077 C allele was
significantly associated with HBV infection (OR=5.1, 95%
confidence interval versus controls, CI: 1.9–13.7; p=0.00093, a
corrected) in the recessive hereditary model, which provided the
highest significance level. A significant association was not found
with the dominant model (Table 1). Notably, in the HBV patients’
group there was a shift from heterozygous to homozygous carriers.
That is, while 90 heterozygous and 14 homozygous carriers of the
minor allele were expected from the Hardy-Weinberg equilibrium,
63 heterozygous and 28 homozygous were observed (p=0.000012).
In contrast, the distribution of rs3077 allele carriers agreed with the
Hardy-Weinberg law in the healthy controls (p=0.88). Finally,
HLA-DPB1 rs9277535 was not associated with HBV infection
(p=1; Table 1) while in both sub-cohorts, the Hardy-Weinberg
equilibrium with respect to rs9277535 was observed (p=0.98 and
0.83 for patients and controls, respectively).
Detailed longitudinal HBV DNA and ALT concentrations were
available from 94 HBV patients (Table 2). Of these, 48 (51%) were
considered inactive HBsAg carriers and 46 (49%) were CHB
patients. No significant association of the HLA-DPA1 and HLA-
DPB1 variants with HBV activity was observed (p=1; Table 1).
While all but five patients had either HBV genotype A or D,
neither the viral nor the host genotypes significantly influenced the
viral activity and logistic regression of the activity status included
none of the candidate factors.
Discussion
The outcome of HBV infection greatly depends on the patient’s
immune response at the time of exposure to the virus [4]. The
underlying regulatory mechanisms of the anti-HBV immune
response are still not understood in full detail. Clinical studies have
shown that in subjects who achieve spontaneous clearance from
acute HBV infection, a strong T cell response involving both HLA
class II-restricted CD4+ helper T cells and HLA class I-restricted
CD8+ cytotoxic T cells was present [4,19]. Indeed, antigen
presentation to CD4+ T cells by HLA class II molecules is believed
to be crucial for the host’s immune response against HBV infection
[20]. This T cell response seems to be significantly attenuated in
patients who develop chronic HBV infection.
HLA class II molecules are classified in three isotypes, including
HLA-DR, HLA-DQ and HLA-DP. HLA-DPs are highly
polymorphic and functional analyses suggest a key role for
HLA-DPs in T cell allorecognition and peptide binding [21].
Therefore, polymorphisms in the HLA-DP gene locus may directly
influence the HLA class II-mediated immune response to HBV
infection. Consequently, HLA-DP gene polymorphisms may not
only be implicated in the development of HBV persistence but
may also be involved in determining different clinical outcomes of
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viremic ‘‘inactive’’ HBsAg carrier status. In a genome-wide
association study, rs3077 and rs9277535 had been identified as
the SNPs with the highest significance level of an association with
HBV infection [9]. More recently, rs3077 and rs9277535 were
reported to be strongly associated with decreased mRNA
expression of HLA-DPA1 and HLA-DPB1, respectively. Thus,
lower expression of HLA-DPA1 and HLA-DPB1 may be associated
with increased risk of chronic HBV infection [22]. Furthermore,
the exchange of the HLA-DPB1 rs9277535 wild type allele A by
the minor G allele may create a new CpG methylation site.
However, a functional consequence is not likely as this SNP is
located in the 39 UTR and as an in-silico analysis [23] did not
identify a CpG island in the region surrounding the rs9277535
polymorphism.
As the first studies and reproductions were performed in Asian
HBV patients only [10,11,12,13], a first finding of the present
study was that a highly significant association between a HLA-
DPA1 rs3077 variant allele and HBV infection was also observed
in Caucasians. Interestingly, the C allele was the minor allele in
our study cohort and it had an allelic frequency of 18% in healthy
controls in the present study. Our observation was supported by
published European HapMap cohorts (CEU population) that
show C-allele frequencies of 12–16% (http://hapmap.ncbi.nlm.
nih.gov/). Its higher frequency in HBV-infected patients vs.
healthy controls was also supported by the HapMap CEU
frequency that lay outside the binomial confidence interval of
20–26.8% observed in the present cohort of HBV-infected patients
(Table 1) and a x
2 goodness-of-fit test versus the largest probability
of 0.16 according to the HapMap CEU cohort (p=0.036). The
association followed the recessive model, which means that
carriage of the minor C allele already sufficed to alter the risk of
HBV inoculation whereas in Asians the association was seen in the
dominant model for the minor T allele, which was a protective
factor for persistent HBV infection. Our findings differ from those
previously published to the extent that carriage of the minor C
allele was associated with an increased risk for HBV infection in
Caucasians, while the minor T allele was a protective factor for
HBV infection in Asians. Together, these different studies show
that the C allele was more frequently observed in both Asian and
Caucasian HBV carriers.
The major finding of the present study was that the highly
significant association with HBV infection did not extend to an
association with the progression and activity of HBV infection.
That is, no differences in allelic frequencies were observed
between patients with more progressive CHB infection and those
with inactive HBsAg carrier status. Likewise, rs3077 did not show
a significant association with HBV-related cirrhosis or hepatocel-
lular carcinoma in previously published reports [10,12]. However,
one limitation of our study is the relatively small sample size of
each HBV patient group. Therefore, our findings need to be
confirmed in larger, multi-national patient cohorts.
Our findings disappointed expectations of a clinical utility of
HLA-DP genotyping information for decisions regarding monitor-
ing and therapy initiation in patients with persistent HBV
infection, which was the primary aim of this study. Ideally, such
information could provide predictive information about whether
the infection can be expected to remain stable with minimal or no
liver damage or whether it progresses to active CHB and liver
damage needs to be prevented by therapy initiation. Considering
the small sample size, the present results do not completely exclude
an association of HLA-DP genetics with the progress of HBV
infection; however, the present results provide no bases that a
major clinical relevance for therapy decisions for the single HBV
patient will be obtained.
A third finding was that the association of rs9277535 in HLA-
DPB1 could not be reproduced in Caucasian HBV patients.
Importantly, the minor G allele frequency was not rare in controls
(24%) and similar frequencies have been reported from European
HapMap cohorts (14%–30%). This reflects the previously
observed stronger association of rs9277535 with HBV infection
in Japanese as compared with Chinese. Both SNPs are found in
the 39 untranslated region of HLA-DPA1 and HLA-DPB1,
respectively and no functional effects for these two SNPs have
been reported so far. Due to their distant location, it is highly
unlikely that these polymorphisms lead to a changed amino acid
sequence that directly affects the antigen-binding site. The SNPs
may serve as proxy markers for closer, yet to be identified
functional HLA-DP polymorphisms. To exclude that the negative
finding was due to a different haploblock structure in Caucasians
than in Asians, we analyzed several more SNPs in both genes
(HLA-DPA1 rs2301220, HLA-DPB1 rs rs3135021, rs3128917,
rs3117222, rs9380343) and found that the haploblock structure
[15], separately for each gene, agreed with that reported from
Asians (details not shown).
Reasons for non-agreement with the Hardy-Weinberg equilib-
rium include selection, familial relationship, assay error and
accidental violations [24]. While the last one can never be
excluded, familial relationship did not apply as the patients had
not been related with each other, and assay error is unlikely since
the Hardy-Weinberg equilibrium was observed in the control
group and careful validation with the inclusion of a positive control
sample for each genotype reduced the possible assay error.
Therefore, the most likely reason for the violation of the Hardy-
Weinberg law is that the immune response is greatly diminished in
homozygous carriers who are therefore a selected population
among carriers of persistent HBV infection.
The present results showed a highly significant association of a
common variant in the HLA-DPA1 locus with HBV infection in
European patients of Caucasian ethnicity, extending the associa-
tion from Asians. However, this finding has currently no major
clinical implications, as differentiation between clinical courses of
HBV infection is not possible and therefore, knowledge of the
HLA-DPA1 genotype cannot be translated into personalized anti-
HBV therapy approaches in Caucasians.
Table 2. Clinical characteristics of patients with persistent
HBV infection (n=201).
All patients IC CHB
Mean age 6 SD in years 42614 42613 46616
Male gender, n (%) 128 (64) 21 (44) 36 (78)
BMI (kg/m
2), mean 6 SD 26652 6 652 6 65
ALT, mean 6 SD 666101 26610 1316152
HBV-DNA, mean 6 SD log10 IU/ml 4.462.8 2.061.0 6.862.4
HBV-Genotype*
A, n (%) 20 (30) 6 (24) 7 (39)
D, n (%) 42 (63) 18 (72) 8 (44)
Characteristics are shown for all patients as well as inactive HBsAg carriers
(n=48) and active CHB patients (n=46) in whom longitudinal data were
available.
IC, inactive HBsAg carriers; CHB, active chronic hepatitis B;
*HBV genotype was available in 67 patients (25 in IC and 18 in CHB).
doi:10.1371/journal.pone.0032605.t002
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